lung cancer: what’s new and what’s old? presented by leora horn at 2014 asco annual meeting

Lung Cancer:<br />What’s New and What’s Old?

Presented By Leora Horn at 2014 ASCO Annual Meeting

Outline Slide

Presented By Leora Horn at 2014 ASCO Annual Meeting

Slide 3

Presented By Leora Horn at 2014 ASCO Annual Meeting

LUX-Lung 3 and 6: design

Presented By Leora Horn at 2014 ASCO Annual Meeting

Combined OS analysis: common mutations (n=631)

Presented By Leora Horn at 2014 ASCO Annual Meeting

Combined OS analysis: mutation categories

Presented By Leora Horn at 2014 ASCO Annual Meeting

JO25567 Study Design

Presented By Leora Horn at 2014 ASCO Annual Meeting

Primary endpoint: PFS by independent review

Presented By Leora Horn at 2014 ASCO Annual Meeting

PFS by EGFR Mutation Type

Presented By Leora Horn at 2014 ASCO Annual Meeting

Acquired Resistance to EGFR TKIs

Presented By Leora Horn at 2014 ASCO Annual Meeting

Phase I Trials With Third Generation EGFR Inhibitors

Presented By Leora Horn at 2014 ASCO Annual Meeting

Phase I Trials

Presented By Leora Horn at 2014 ASCO Annual Meeting

AZD9291: Response rate* in T790M+ (central test)

Presented By Leora Horn at 2014 ASCO Annual Meeting

CO-1686: Best response in Phase 1 and early <br />Phase 2 expansion cohort patients

Presented By Leora Horn at 2014 ASCO Annual Meeting

HM61713: Response in T790M Cohort

Presented By Leora Horn at 2014 ASCO Annual Meeting

RADIANT Trial Design

Presented By Leora Horn at 2014 ASCO Annual Meeting

Disease-free Survival KM Plot – FAS

Presented By Leora Horn at 2014 ASCO Annual Meeting

Slide 18

Presented By Leora Horn at 2014 ASCO Annual Meeting

Slide 19

Presented By Leora Horn at 2014 ASCO Annual Meeting

Summary

Presented By Leora Horn at 2014 ASCO Annual Meeting

PROFILE 1014 Study Design

Presented By Leora Horn at 2014 ASCO Annual Meeting

Primary Endpoint Met: Crizotinib Superior to Pemetrexed-based Chemotherapy in Prolonging PFSa

Presented By Leora Horn at 2014 ASCO Annual Meeting

ASCEND-1 Study Design

Presented By Leora Horn at 2014 ASCO Annual Meeting

Progression-Free Survival in Patients with ALK+ NSCLC

Presented By Leora Horn at 2014 ASCO Annual Meeting

Summary

Presented By Leora Horn at 2014 ASCO Annual Meeting

REVEL: Study Design

Presented By Leora Horn at 2014 ASCO Annual Meeting

Overall Survival<br />ITT Population

Presented By Leora Horn at 2014 ASCO Annual Meeting

Study Design: Squire

Presented By Leora Horn at 2014 ASCO Annual Meeting

Slide 29

Presented By Leora Horn at 2014 ASCO Annual Meeting

Summary

Presented By Leora Horn at 2014 ASCO Annual Meeting

CREST Trial Design

Presented By Leora Horn at 2014 ASCO Annual Meeting

Overall survival

Presented By Leora Horn at 2014 ASCO Annual Meeting

PCI in SCLC: Trial Design

Presented By Leora Horn at 2014 ASCO Annual Meeting

Time to Brain Metastasis

Presented By Leora Horn at 2014 ASCO Annual Meeting

Overall Survival

Presented By Leora Horn at 2014 ASCO Annual Meeting

Summary

Presented By Leora Horn at 2014 ASCO Annual Meeting

KEYNOTE-001: First line therapy with MK3475 in patients with PD-L1 positive NSCLC

Presented By Leora Horn at 2014 ASCO Annual Meeting

Antitumor Activity by MK-3475 Dose

Presented By Leora Horn at 2014 ASCO Annual Meeting

Conclusions

Presented By Leora Horn at 2014 ASCO Annual Meeting